Coral Springs, FLNCT07540221Now EnrollingIRB Ready

CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Clinical Trial in Coral Springs, FL

Access cutting-edge cidp (chronic inflammatory demyelinating polyradiculoneuropathy) treatment through this clinical trial at a research site in Coral Springs. Study-provided care at no cost to qualified participants.

Sponsored by Grifols Therapeutics LLC

Quick Self-Assessment

See if you qualify for this Coral Springs location

Preparing your pre-screening questions…

Expert Care in Coral Springs

Access cidp (chronic inflammatory demyelinating polyradiculoneuropathy) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cidp (chronic inflammatory demyelinating polyradiculoneuropathy) treatment provided free

Apply for This Coral Springs Location

Check if you qualify for this cidp (chronic inflammatory demyelinating polyradiculoneuropathy) clinical trial in Coral Springs, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Coral Springs

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Coral Springs site if eligible
  4. 4Begin participation

About This CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Study in Coral Springs

The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP. Participants with CIDP will first have up to 28 days of screening to make sure they can join the study. Those who qualify will then start a 19-week treatment period with Gamunex-C. During this period, they will receive Gamunex-C through a vein once every 3 weeks, for a total of 7 doses. Approximately, one week after their last Gamunex-C dose, they will begin a 16-week treatment period with XEMBIFY under the skin, once a week for a total of 16 doses. Blood samples will be collected during both treatment periods to measure IgG level in the blood.

Sponsor: Grifols Therapeutics LLC

Who Can Participate

Inclusion Criteria

Have typical CIDP or a CIDP variant according to the 2021 criteria established by the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS). The level of diagnostic certainty may be CIDP or possible CIDP.
Participants ≤ 90 kg in body weight and requiring an IGIV dose equivalent to 0.3-1.0 g/kg every three weeks (Q3W) inclusive and between 20-90 g of IGIV Q3W inclusive.
Clinically stable on IGIV, defined as no recent change in CIDP treatment or experienced a CIDP relapse requiring treatment, within 12 weeks prior to Screening and through baseline visit.

Exclusion Criteria

Diagnosis of polyneuropathy of any other cause (including multifocal motor neuropathy; monoclonal gammopathy of uncertain significance with anti-myelin-associated glycoprotein IgM antibodies; hereditary demyelinating neuropathy; polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome; lumbosacral radiculoplexus neuropathy; polyneuropathy associated with diabetes mellitus; polyneuropathy associated with systemic illnesses; or drug or toxin induced polyneuropathy).
Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study such as the following:
current malignancy or history of allogeneic bone marrow/stem cell transplant,
cardiac insufficiency (New York Heart Association classes III/IV), cardiomyopathy, significant cardiac arrhythmia requiring treatment, unstable or advanced ischemic heart disease, congestive heart failure or severe hypertension
chronic kidney disease stage IV or V
an acquired medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/µL \[1.0 × 10\^9/L\]), or human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome
known bleeding disorders
severe skin disease at the planned injection sites
alcohol, drug or medication abuse, or
other disorders where IGSC therapy would be contraindicated during the study.
History of a thrombotic episode (including deep vein thrombosis, known hypercoagulable state, myocardial infarction, pulmonary embolism, or thromboembolic stroke)
Known allergic or other severe adverse reactions to blood products including intolerability to previous IVIG up to 1 g/kg Q3W, history of hemolysis after IVIG infusion, aseptic meningitis, recurrent severe headache, hypersensitivity, or severe generalized skin reaction
Has had a CIDP relapse requiring treatment modification within 12 weeks prior to Screening or between Screening and baseline visit
Treatment with any of the following:
alemtuzumab or rituximab within 12 months of Screening.
cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or fragment crystallizable receptor (FCRn) blockers, within six months of Screening
plasma exchange or complement inhibitors within three months of Screening.
changes to the following treatment within three months of Screening: methotrexate, azathioprine, or mycophenolate or any other immunosuppressants within six months of Screening
participants on corticosteroids ≥ 20 mg/day prednisone equivalent. Participants on low dose corticosteroids (\< 20 mg/day prednisone equivalent) may be enrolled if dose has been stable over the last three months prior to Screening and the dosage is not likely to be adjusted during the duration of the trial (inhaled or topical corticosteroids are allowed).
Participants requiring an IGIV dose equivalent to:
greater than 1.0 g/kg every three weeks (Q3W) or
less than 0.3 g/kg Q3W or
greater than 90 g of IGIV Q3W or
less than 20 g of IGIV Q3W.
Known IgA deficient patients with known antibodies against IgA
Known significant proteinuria (≥ 3+ or known urinary protein loss \>1 g/24 hours or nephrotic syndrome), acute renal failure, are on dialysis, and/or have severe renal impairment on Screening laboratory testing (blood urea nitrogen \[BUN\] \> 3 times the upper limit of normal \[ULN\] or creatinine more than 1.5 times ULN).
Screening values of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceeding ≥ 2.5 times the ULN for the expected normal range for the testing laboratory.
Hemoglobin levels \< 10 g/dL at Screening.
Current administration of anti-coagulation therapy which would make IGSC administration inadvisable per investigator judgement (i.e., vitamin K antagonists, nonvitamin K antagonist oral anticoagulants \[e.g., dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa\], and parenteral anticoagulants \[e.g., fondaparinux\]).
Known hyperviscosity syndrome.
Known HIV, chronic hepatitis B virus (HBV), or chronic hepatitis C virus (HCV) infection.
Participation in another clinical trial within 30 days or if known, 5 half-lives of the interventional product prior to Screening (observational studies without investigative treatments \[non-interventional\] are permitted).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Coral Springs?

Yes, this clinical trial (NCT07540221) has an active research site in Coral Springs, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Treatment Options in Coral Springs, FL

If you're searching for cidp (chronic inflammatory demyelinating polyradiculoneuropathy) treatment options in Coral Springs, FL, this clinical trial (NCT07540221) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Coral Springs research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cidp (chronic inflammatory demyelinating polyradiculoneuropathy) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cidp (chronic inflammatory demyelinating polyradiculoneuropathy) clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Coral Springs, FL

See all multiple myeloma clinical trials recruiting in Coral Springs — not just this study.

Browse Multiple Myeloma Trials in Coral Springs →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsAlzheimers Disease TrialsNeuropathy TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Coral Springs?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Coral Springs, FL